TRINITY BIOTECH PLC
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Trinity Biotech
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Trinity Biotech operates in the healthcare diagnostics industry, focusing on research, development, and manufacturing of medical diagnostic solutions. The company conducts its operations across three primary business segments: Clinical Laboratory, Laboratory Services, and Point of Care. Its offerings and developmental projects include continuous glucose monitoring testing devices and Premier instruments, alongside clinical testing capabilities. The organization serves a global customer base comprising healthcare clients and laboratory purchasers located across the Americas, Europe, Asia, and Africa.
The company's geographic footprint and operational scale extend internationally, with named operating entities, facilities, and regional exposure in Ireland, the United States, Sweden, and Luxembourg. Its corporate structure includes specialized units such as Trinity Biotech Manufacturing, Trinity Research, Clark Laboratories, and Fiomi Diagnostics. While the provided text references primary activities and regional disclosures spanning Europe and North America, it does not explicitly designate a formal corporate headquarters location.
Summary of the business section of Trinity Biotech's latest annual report, written by StockData.
Company profile
Company
- Legal name
- TRINITY BIOTECH PLC
- Headquarters
- Wicklow, Ireland
- Address
- Ida Business Park, Bray
- Phone
- 01135312955111
- Employees
- 287, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- L2
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON, Dublin, Ireland
Stock & identifiers
- Ticker
- TRIB
- Exchange
- Nasdaq
- Shares outstanding
- 374M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- Stock splits
- 1-for-30 reverse, Jul 24, 2026; 1-for-5 reverse, Feb 23, 2024; 1-for-4 reverse, Jun 2, 2005
- SEC CIK
- 888721
- CUSIP
- 896438504
- ISIN
- US8964385046
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Paul Murphy | Interim CFO | – |
| Ronan O'Caoimh | Director | 486,208 |
| John Gillard | Director | 10,000 |
| John Paul Tivnan | Director | – |
| Andrew Omidvar | Director | – |
Employees
Headcount reported in annual reports
“The following table details certain data on the average number of employees of Trinity Biotech and its consolidated subsidiaries, including full-time, part-time, and temporary personnel who work under the direction and supervision of the Company: … Total workforce 287 401 380”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2025 | Late filing | Notification of late filing |
| May 1, 2023 | Late filing | Notification of late filing |
| May 1, 2019 | Late filing | Notification of late filing |
| Jul 1, 2003 | Late filing | Notification of late filing |